Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Jakafi (ruxolitinib) - Incyte
acetylcysteine solution - Generic mfg.
Adcetris (brentuximab vedotin) - Takeda, Pfizer
Acute Liver Failure as the Initial Manifestation of EBV-Associated Aggressive NK-Cell Leukemia Complicated by Hemophagocytic Lymphohistiocytosis (ACG 2026) - Aug 29, 2026 - Abstract #P4239; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "She was treated with N-acetylcysteine for acute liver failure and placed on continuous renal replacement therapy...She was transferred to the hematology service and treated with nivolumab, ruxolitinib, and brentuximab...Acute liver failure is an unusual presentation of the disease and generally occurs when there is a significant EBV viral load. Prompt consideration of HLH and early bone marrow evaluation are critical for establishing the diagnosis and initiating disease-directed therapy." 
Acute Kidney Injury • CNS Disorders • Dyslipidemia • Epstein-Barr Virus Infections • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Hypertriglyceridemia • Immunology • Infectious Disease • Leukemia • Liver Failure • Nephrology • Rare Diseases • Renal Disease
https://acg2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=R01PT1FGR0UyNjkyNQ&PosterID=831374&rnd=0.8108432
 
Miguel Gomez; MD; Shuji Mitsuhashi; MBBS; Patrick Kamath; MD
 
Aug 29, 2026
 
Prev Next